ストックスクリーナーアプリを入手
145.70
3.84%
5.39
アフターアワーズ：
145.70
前日終値:
$140.31
開ける：
$141.49
24時間の取引高:
152.93K
Relative Volume:
0.58
時価総額：
$2.09B
収益：
$1.30M
当期純損益:
$-49.30M
株価収益率:
-34.95
EPS:
-4.1688
ネットキャッシュフロー:
$-25.01M
1週間 パフォーマンス:
-4.66%
1か月 パフォーマンス:
+34.08%
6か月 パフォーマンス:
+44.21%
1年 パフォーマンス:
+485.14%
1日の値動き範囲:
$138.29
$147.96
1週間の範囲:
$135.00
$150.40
52週間の値動き範囲:
$24.07
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
名前
Palvella Therapeutics Inc
セクター
電話
(484) 253-1461
住所
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
145.70 | 2.01B | 1.30M | -49.30M | -25.01M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Mizuho | Outperform |
| 2025-12-05 | 開始されました | BTIG Research | Buy |
| 2025-12-04 | 開始されました | Craig Hallum | Buy |
| 2025-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-06 | 開始されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-04-09 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-26 | 開始されました | Stifel | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-05 | 開始されました | TD Cowen | Buy |
| 2024-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Palvella Therapeutics Inc (PVLA) 最新ニュース
PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz
Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart
Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire
Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com
Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Palvella submits FDA NDA for QTORIN gel - grafa.com
Palvella submits first module of NDA for rare skin disease therapy - Investing.com
Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - Yahoo Finance
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - The Motley Fool
Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA) - TradingView
Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6) - TradingView
Canaccord reiterates Palvella stock rating on physician survey data - Investing.com UK
Enterprise value to revenue forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBIT forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
A40RA6 Forecast — Price Target — Prediction for 2027 - TradingView
Palvella shares advance after FDA grants rolling review for rare disease therapy - MSN
Price to earnings forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Canaccord reiterates Palvella stock rating on physician survey data By Investing.com - Investing.com South Africa
Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k - Moomoo
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227 - Moomoo
Price to sales forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Price to book forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBITDA forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250 - Moomoo
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com - Investing.com India
Palvella stock rises on FDA rolling review for rare disease drug - Investing.com
Form 4 Palvella Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock - Investing.com
Palvella Therapeutics granted FDA rolling review for QTORIN - grafa.com
Palvella Therapeutics Inc (PVLA) 財務データ
収益
当期純利益
現金流量
EPS
Palvella Therapeutics Inc (PVLA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer |
Jun 17 '26 |
Sale |
110.73 |
4,302 |
476,373 |
0 |
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):